As a science-driven industry that aims to address some of the world’s biggest health care challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19.

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, today confirmed that having already mobilized on an unprecedented scale to respond to the COVID-19 pandemic, they commit to do more. The biopharmaceutical industry commits to accelerate its effort to use its skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world as a matter of urgency.

For the full article, please follow this link: Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis

Published on 19 March 2020, IFPMA website